Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies

References

• Rieckmann P, Toyka KV, Bassetti C et al. Escalating immunotherapy of multiple sclerosis – new aspects and practical application. J. Neurol.251, 1329–1339 (2004).
   PubMed Web of Science ®Google Scholar
• Boster A, Edan G, Frohman E et al. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol.7, 173–183 (2008).
   PubMed Web of Science ®Google Scholar
• Interferon β-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology43, 655–661 (1993).
   PubMed Web of Science ®Google Scholar
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet352, 1498–1504 (1998).
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol39, 285–294 (1996).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind, placebo-controlled trial. 1995. Neurology57, S16–S24 (2001).
   PubMed Web of Science ®Google Scholar
• Filippini G, Munari L, Incorvaia B et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet361, 545–552 (2003).
   PubMed Web of Science ®Google Scholar
• Twork S, Nippert I, Scherer P, Haas J, Pöhlau D, Kugler J. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. Curr. Med. Res. Opin.23, 1209–1215 (2007).
   PubMed Web of Science ®Google Scholar
• Rostami-Yazdi M, Clement B, Schmidt TJ, Schinor D, Mrowietz U. Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. J. Invest. Dermatol. (2008) (Epub ahead of print).
   Google Scholar
• Litjens NH, Burggraaf J, van Strijen E et al. Pharmacokinetics of oral fumarates in healthy subjects. Br. J. Clin. Pharmacol.58, 429–432 (2004).
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br. J. Dermatol.141, 424–429 (1999).
   PubMed Web of Science ®Google Scholar
• Hoxtermann S, Nuchel C, Altmeyer P. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Dermatology196, 223–230 (1998).
   PubMed Web of Science ®Google Scholar
• Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J. Invest Dermatol.121, 1383–1388 (2003).
   PubMed Web of Science ®Google Scholar
• de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur. J. Immunol.26, 2067–2074 (1996).
   PubMed Web of Science ®Google Scholar
• Lehmann M, Risch K, Nizze H et al. Fumaric acid esters are potent immunosuppressants: inhibition of acute and chronic rejection in rat kidney transplantation models by methyl hydrogen fumarate. Arch. Dermatol. Res.294, 399–404 (2002).
   Google Scholar
• Litjens NH, Rademaker M, Ravensbergen B et al. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur. J. Immunol.34, 565–575 (2004).
   PubMed Web of Science ®Google Scholar
• Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J. Invest Dermatol.116, 203–208 (2001).
   PubMed Web of Science ®Google Scholar
• Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br. J. Dermatol.139, 390–395 (1998).
   PubMed Web of Science ®Google Scholar
• Sebok B, Bonnekoh B, Vetter R, Schneider I, Gollnick H, Mahrle G. The antipsoriatic dimethyl-fumarate suppresses interferon-gamma-induced ICAM-1 and HLA-DR expression on hyperproliferative keratinocytes. Quantification by a culture plate-directed APAAP-ELISA technique. Eur. J. Dermatol.8, 29–32 (1998).
   PubMed Web of Science ®Google Scholar
• Loewe R, Holnthoner W, Gröger M et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-κB/p65 in human endothelial cells. J. Immunol.168, 4781–4787 (2002).
   PubMed Web of Science ®Google Scholar
• Vandermeeren M, Janssens S, Borgers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem. Biophys. Res. Commun.234, 19–23 (1997).
   PubMed Web of Science ®Google Scholar
• Stoof TJ, Flier J, Sampat S, Nieboer C, Tensen CP, Boorsma DM. The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br. J. Dermatol.144, 1114–1120 (2001).
   PubMed Web of Science ®Google Scholar
• Bureau F, Vanderplasschen A, Jaspar F et al. Constitutive nuclear factor-κB activity preserves homeostasis of quiescent mature lymphocytes and granulocytes by controlling the expression of distinct Bcl-2 family proteins. Blood99, 3683–3691 (2002).
   PubMed Web of Science ®Google Scholar
• Lehmann JC, Listopad JJ, Rentzsch CU et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J. Invest. Dermatol.127, 835–845 (2007).
   PubMed Web of Science ®Google Scholar
• Schmidt TJ, Ak M, Mrowietz U. Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine - preparation of S-substituted thiosuccinic acid esters. Bioorg. Med. Chem.15, 333–342 (2007).
   PubMed Web of Science ®Google Scholar
• Nibbering PH, Thio B, Zomerdijk TP et al. Effects of monomethylfumarate on human granulocytes. J. Invest Dermatol.101, 37–42 (1993).
   PubMed Web of Science ®Google Scholar
• Zhu K, Mrowietz U. Enhancement of antibacterial superoxide-anion generation in human monocytes by fumaric acid esters. Arch. Dermatol. Res.297, 170–176 (2005).
   PubMed Web of Science ®Google Scholar
• Wierinckx A, Brevé J, Mercier D, Schultzberg M, Drukarch B, Van Dam AM. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J. Neuroimmunol.166, 132–143 (2005).
   PubMed Web of Science ®Google Scholar
• Schweckendiek W. Treatment of psoriasis vulgaris. Med. Monatsschr.13, 103–104 (1959).
   PubMedGoogle Scholar
• Nieboer C, de Hoop D, van Loenen AC, Langendijk PN, van Dijk E. Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. J. Am. Acad. Dermatol.20, 601–608 (1989).
   PubMed Web of Science ®Google Scholar
• Altmeyer PJ, Matthes U, Pawlak F et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J. Am. Acad. Dermatol.30, 977–981 (1994).
   PubMed Web of Science ®Google Scholar
• Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J. Am. Acad. Dermatol.27, 769–771 (1992).
   PubMed Web of Science ®Google Scholar
• McCarey D, McInnes IB. Psoriatic arthritis: current topics. Curr. Rheumatol. Rep.9, 442–448 (2007).
   Google Scholar
• Altmeyer P, Hartwig,R, Matthes U. Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients. Hautarzt47, 190–196 (1996).
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br. J. Dermatol.138, 456–460 (1998).
   PubMed Web of Science ®Google Scholar
• Kreuter A, Knierim C, Stücker M, et al. Fumaric acid esters in necrobiosis lipoidica: results of a prospective noncontrolled study. Br. J. Dermatol.153, 802–807 (2005).
   Google Scholar
• Nowack U, Gambichler T, Hanefeld C, Kastner U, Altmeyer P. Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters. BMC Dermatol.2, 15 (2002).
   Google Scholar
• Wakkee M, Thio HB. Drug evaluation: BG-12, an immunomodulatory dimethylfumarate. Curr. Opin. Investig. Drugs8, 955–962 (2007).
   PubMed Web of Science ®Google Scholar
• Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain129, 1953–1971 (2006).
   PubMed Web of Science ®Google Scholar
• Herrero-Herranz E, Pardo LA, Gold R, Linker RA. Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol. Dis.30, 162–173 (2008).
   Google Scholar
• Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin. Exp. Immunol.145, 101–107 (2006).
   PubMed Web of Science ®Google Scholar
• Lukashev M, Zeng W, Goelz S et al. Activation of Nrf2 and modulation of disease progression in EAE models by BG00012 (dimethyl fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotective modalities. Mult. Scler.13(Suppl. 2), S149 (2007).
   PubMed Web of Science ®Google Scholar
• Schimrigk S, Brune N, Hellwig K et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur. J. Neurol.13, 604–610 (2006).
   PubMed Web of Science ®Google Scholar
• BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative – Fumapharm/Biogen Idec. Drugs R & D6, 229–230 (2005).
   PubMedGoogle Scholar
• Kappos L, Miller D, MacManaus D. BG00012, a novel fumarate is effective in patients with relapsing–remitting multiple sclerosis. Mult. Scler.12(Suppl. 1), 85 (2006).
   Google Scholar
• Stüve O, Youssef S, Weber MS et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J. Clin. Invest116, 1037–1044 (2006).
   PubMed Web of Science ®Google Scholar
• Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol.55, 458–468 (2004).
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol.6, 259–274 (1996).
   PubMed Web of Science ®Google Scholar